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ORIGINAL ARTICLE
Coculturing Human Islets with Proangiogenic
Support Cells to Improve Islet Revascularization
at the Subcutaneous Transplantation Site
Mijke Buitinga, PhD,1,* Karolina Janeczek Portalska, PhD,2,* Dirk-Jan Cornelissen, MSc,1 Jacqueline Plass, PhD,1
Maaike Hanegraaf, BSc,3 Françoise Carlotti, PhD,3 Eelco de Koning, MD, PhD,3–5 Marten Engelse, PhD,3
Clemens van Blitterswijk, PhD,6 Marcel Karperien, PhD,1 Aart van Apeldoorn, PhD,1** and Jan de Boer, PhD7
While subcutaneous tissue has been proposed as a clinically relevant site for pancreatic islet transplantation, a major
issue of concern remains, which is its poor vascular state. In an effort to overcome this limitation, we present an
efficient and reproducible method to form human composite islets (CIs) with proangiogenic cell types in a con-
trolled manner using nonadherent agarose microwell templates. In this study, we assessed the three-dimensional
structure, function, and angiogenic potential of human CIs with human mesenchymal stromal cells (hMSCs), with
or without human umbilical vein endothelial cells (HUVECs), and preconditioned hMSCs (PC-hMSCs) in EGM-2
under shear stress. Distinct cellular rearrangements could be observed in CIs, but islet functionality was maintained.
In vitro angiogenesis assays found significantly enhanced sprout formation in case of CIs. In particular, the number
of sprouts emanating from CIs with PC-hMSCs was significantly increased compared to other conditions. Sub-
sequent in vivo assessment confirmed the proangiogenic potential of CIs. However, in contrast to our in vitro
angiogenesis assays, CIs with hMSCs and HUVECs exhibited a higher in vivo angiogenic potential compared to
control islets or islets combined with hMSCs or PC-hMSCs. These findings highlight the importance and necessity
of verifying in vitro studies with in vivo models to reliably predict, in this case, revascularization outcomes.
Regardless, we demonstrate here the therapeutic potential of CIs with proangiogenic support cells to enhance islet
revascularization at a clinically relevant, although poorly vascularized, transplantation site.
Introduction
Clinical trials have demonstrated the ability of allo-geneic islet transplants to regulate blood glucose levels in
patients with type 1 diabetes and labile glycemic control.1–3
The main benefit of this procedure compared to whole-organ
transplantation is the significant reduction in glycemic
fluctuations while having reduced postoperative trauma and
complication rates. In clinical practice, the transplantation
site of choice is the liver. However, the long-term insulin
independence rate at this site is disappointing due to sub-
stantial islet loss, necessitating the use of at least two donor
organs to cure one patient.1,3 There is strong evidence that
site-specific factors contribute to this islet loss in the liver,
such as the exposure to high concentrations of immuno-
suppressants4 and the instant blood-mediated inflammatory
reaction.5,6 This has led to the search for alternative trans-
plantation sites.
The subcutaneous space is a relevant candidate for islet
transplantation because the transplant and biopsy proce-
dures for this site are simple with minimal invasion. Fur-
thermore, this site holds the capacity to transplant a sufficient
amount of islets. However, a major challenge of this site is
its poor vascularization state.7 Since the vascular network is
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important to maintain the islets’ oxygen-dependent metab-
olism and their ability to quickly secrete insulin in response
to changes in blood glucose levels, a reduced vasculariza-
tion will affect both islet survival and function. Therefore,
the vascular connections need to be re-established as fast as
possible after transplantation.
Hence, various attempts have been made to improve vas-
cularization of islets after transplantation. One of these attempts
is to increase the action of proangiogenic factors to stimulate
the proliferation, migration, and maturation of endothelial
cells.8 Precise control over timing, dose delivery, and effect
duration of these factors remains a major challenge to obtain
mature functional blood vessels within the islets. An alternative
approach is to directly use endothelial cells, endothelial pro-
genitor cells, or mesenchymal stem cells (MSCs). Johansson
et al.9 have shown that coating human islets with endothelial
cells initiates the formation of vessel-like structures in vitro,
without impairing islet functionality. The sprouting capacity of
endothelial cell-coated islets was further improved by the ad-
dition of MSCs. Other studies have shown that cotransplanting
islets with mature endothelial cells,10 stromal cells,11–15 or
endothelial progenitor cells16–18 derived from various sources
can induce neovascularization, resulting in enhanced islet re-
vascularization and better function, regardless of whether the
implantation site was underneath the kidney capsule10,11,14,16,18,19
or the liver.12,15,17 However, a comparison of islet revascu-
larization at the subcutaneous transplantation site when using
different support cell types has not been performed.
In the current study, we report an efficient and repro-
ducible method to form human CIs with proangiogenic cell
types in a controlled manner using nonadherent agarose
microwell templates. Recently, we have shown that pre-
conditioning of human mesenchymal stromal cells (hMSCs)
in EGM-2 under shear stress, factors known to play an
important role in triggering endothelial differentiation of
MSCs,20–23 significantly improves the vascularization of
Dex-g-HA gels after subcutaneous implantation.24 There-
fore, in this study, we directly compare the angiogenic po-
tential of composite islets (CIs) formed with a mixture of
hMSCs and human umbilical vein endothelial cells (HU-
VECs), hMSCs, or preconditioned hMSCs (PC-hMSCs) to
that of control islets at the subcutaneous transplantation site.
Materials and Methods
Islets of Langerhans isolation and culture
Human islets of Langerhans were isolated from pancreas
obtained from organ donors (Human Islet Isolation Laboratory,
Leiden University Medical Center, Leiden, The Netherlands).
Islets were used in the studies if they could not be used for
clinical transplantation, and if research consent was available,
according to national laws. Islets were cultured in islet culture
medium (CMRL-1066; Cellgro, Mediatech, VA), supple-
mented with 10% fetal bovine serum (FBS) (Lonza, Verviers,
Belgium), 100 U/mL penicillin (GIBCO, Bleiswijk, The
Netherlands), and 10mg/mL streptomycin (GIBCO).
hMSC isolation and culture
Bone marrow aspirates were obtained from donors with
written informed consent (Medisch Spectrum Twente, En-
schede, The Netherlands), and hMSCs were isolated and pro-
liferated as described previously.24 Briefly, aspirates were
resuspended using a 20-G needle and plated at a density of 0.5
million mononucleated cells per cm2. Cells were grown in
MSC proliferation medium (alpha-MEM; GIBCO), supple-
mented with 10% FBS (Lonza), 100 U/mL penicillin (GIBCO),
10mg/mL streptomycin (GIBCO), 2 mM l-glutamine (GIB-
CO), 0.2 mM L-ascorbic acid 2-phosphate magnesium salt
(Sigma-Aldrich, Diegem, Belgium), and 1 ng/mL basic fibro-
blast growth factor (bFGF) (Fisher Scientific, Waltham, MA)
at 37C in a humid atmosphere with 5% CO2. Cells were ex-
panded up to passage 2. For further experiments, hMSCs from
different donors and one immortalized clone (iMSCs, courtesy
of Prof. Ola Myklebost, University of Oslo, Norway)25 were
cultured in basic medium (alpha-MEM supplemented with
10% FBS, 100 U/mL penicillin, 10mg/mL streptomycin, 2 mM
l-glutamine, and 0.2 mM ASAP). HUVECs (Lonza) were
cultured in endothelial growth medium (EGM-2; Lonza).
Preconditioning of hMSCs
For preconditioning, iMSCs (passage 25, for in vitro
sprouting assay) and hMSCs from different donors (passages
1–2) were seeded at a density of 3000 cells per cm2 on tissue
culture plastic in EGM-2 and cultured for 10 days. Next to
growth supplements, shear force has also been shown to play
an important role in triggering endothelial differentiation of
MSCs.20–23 Therefore, we applied shear force after 1 day of
static culture using an orbital shaker (20 rpm), as described
previously.24 Cells that were cultured according to this pro-
tocol will be referred to as PC-hMSCs.
Cell labeling
When indicated, hMSCs (both naive and preconditioned)
and HUVECs were labeled using CM-DiI (red) or CM-DiO
(green), according to the manufacturer’s protocol (Life
Technologies, Bleiswijk, The Netherlands).
Formation of CIs
Nonadherent agarose microwell chips were prepared by
replica molding as described previously.26,27 Briefly, negative
replicates of patterned polydimethylsiloxane (PDMS; Sylgard
184, Dow Corning, Midland) stamps, each containing 130
pillars with a diameter of 400mm and a height of 200mm,
were prepared using 3% agarose solution (UltraPure Agarose;
Invitrogen, Bleiswijk, The Netherlands). Before cell seeding,
the agarose chips were incubated in EGM-2 for 8 h. To
produce CIs with proangiogenic cells, islets were homoge-
neously seeded in the microwells, after which a cell sus-
pension of hMSCs (1250 cells/islet), a mixture of hMSCs
(625 cells/islet) and HUVECs (1250 cells/islet), or PC-
hMSCs (1250 cells/islet), was added. Subsequently, the
agarose microwell chips were shortly centrifuged at 150 g to
settle the cells with the islets in the microwells. Cells attached
to the surface of the islets within 8 h of culture in EGM-2.
These cell aggregates are referred to as CIs. Medium was
refreshed every day with a 1:1 mixture of EGM-2 and islet
culture medium. Imaging of the CIs was performed using an
EVOS FL Imaging System (Invitrogen).
Immunohistochemistry on whole-mount islets
At day 1 and day 5, CIs and control islets were flushed out
of the agarose chips, resuspended in serum-depleted culture




















































medium, and transferred to Cell-Tak-coated (30 s at 42C;
BD Biosciences, Breda, The Netherlands) Ibidi microscopy
culture chambers (Ibidi, Planegg, Germany). After attach-
ment, islets were fixed in 4% phosphate-buffered parafor-
maldehyde for 25 min at room temperature. Fixation was
followed by three 30-min washes in phosphate buffered
saline (PBS) and a 3-h permeabilization in 0.3% Triton
X-100/PBS. Blocking was performed by o/n incubation in
10% NGS/0.15% Triton X-100/PBS at 4C. Islets were
washed three times for 30 min with antibody diluent buffer
(1% BSA/0.2 Triton X-100) before incubation with pri-
mary antibodies (guinea pig anti-insulin [Abcam, Cambridge,
United Kingdom] 1:100 and rabbit antiglucagon [Vector,
Peterborough, United Kingdom] 1:100, 48 h at 4C), second-
ary antibodies (Alexa 647-conjugated goat anti-guinea pig
[Life Technologies] and Alexa 488-conjugated goat anti-
rabbit [Invitrogen], both 1:200, 48 h at 4C), and DAPI (In-
vitrogen [5 mg/mL], 1:100, 20 min at room temperature).
Samples were subjected to optical sectioning at 0.23-mm in-
crements in axial (z) dimension using Nikon A1 confocal
microscope (Nikon BV, Amsterdam, The Netherlands).
Glucose-induced insulin secretion test
To assess islet functionality, a glucose-induced insulin
secretion test was performed at day 1 and day 5 after CI
formation. Per condition per islet donor, 100 islets were
used. As a control, uncoated islets were cultured in agarose
chips. CI formation was performed in EGM-2, after which
the islets were cultured for 5 days in islet medium, with a
medium change every day. For the glucose-induced insulin
secretion test, 30 islets per condition (in triplicate) were
incubated for 90 min in a modified Krebs Ringer Bicarbo-
nate (KRBH) buffer (115 mM NaCl, 5 mM KCl, 24 mM
NaHCO3, 2.2 mM CaCl2, and 1 mM MgCl2, pH 7.4), sup-
plemented with 20 mM HEPES, 2 mg/mL human serum
albumin (Sanquin, Amsterdam, The Netherlands), and
1.7 mM D-glucose.
Islets were successively incubated for 1 h in KRBH buffer
with 1.7 mM and 16.7 mM D-glucose at 37C. Insulin con-
centration was determined in the supernatants by ELISA
(Mercodia, Uppsala, Sweden). The experiment was per-
formed for three islet donors, each time coated with hMSCs
from different donors.
Sprouting assays on Matrigel and fibrin gel
For the sprouting assays, control islets and hMSC-, HU-
VEC/hMSC-, and PC-hMSC-CIs were placed between two
layers of growth factor-reduced Matrigel (diluted 1:1 in
EGM-2; BD Biosciences) or fibrin gel (2.5 mg/mL fibrino-
gen and 2 mg/mL thrombin; Sigma-Aldrich). For each gel
layer, 1 mL of gel was used. After polymerization, islets
were cultured for 96 h in EGM-2. Islet sprouting was ob-
served over time using an inverted microscope (Nikon
Eclipse TE300). Light microscopy pictures were taken at
different time points (24, 48, and 96 h) using a Nikon DS-L2
camera. The Matrigel sprouting assay was performed with
islets obtained from five different human islet donors, and
the fibrin sprouting assay was performed with islets from
two different donors. Furthermore, hMSCs from five dif-
ferent donors and one clone of iMSCs were used in this
study.25 Sprout formation was manually quantified by a
single person (blinded to the conditions) in minimally 10
islets per condition per time point.
Subcutaneous Matrigel plug angiogenesis assay
To test the angiogenic potential of CIs in vivo, control
islets and hMSC-, HUVEC/hMSC-, and PC-hMSC-CIs were
transplanted subcutaneously in Matrigel plugs in the back of
8-week-old male NMRI-nu mice (Harlan). For this, CIs
were formed for 8 h in the agarose microwells as described
before. Subsequently, islets were flushed out, washed in
EGM-2 (without supplemented growth factors), and re-
suspended in 100mL growth factor-reduced Matrigel (BD
Biosciences). The plugs were allowed to solidify at 37C in
a round-bottom 96-well plate to obtain uniform plugs. After
solidification, the Matrigel plugs were recovered from the
plate and cultured for 8 h in islet culture medium. Per con-
dition, 9 plugs were implanted containing each 200 islets.
Of these plugs, three plugs were prepared using CM-
DiI-prelabeled cells as described before. Before isoflurane
anesthetics, mice were given 0.1 mg/kg buprenorfin (Tem-
gesic, Schering-Plough, Belgium). Four small subcutaneous
pockets were created at each quadrant of the back of the
mouse. In each mouse, all four conditions were transplanted,
but the position of the different conditions was randomized
per animal.
Histochemistry and morphometric analysis
Two weeks after implantation, mice were sacrificed, and
Matrigel plugs were recovered for histological analysis.
Grafts were fixed overnight with 4% (w/v) paraformalde-
hyde at 4C, embedded in paraffin blocks, and sliced into
5-mm sections.
For each Matrigel plug, sections spaced 100 mm apart
were stained for insulin combined with a Masson-Goldner’s
trichrome staining (Merck Chemicals, Darmstadt, Germany)
to determine the amount of perfused blood vessels in and
around the islets. For this, primary antibody rabbit anti-
insulin (1:400; Santa Cruz Biotechnology, Heidelberg,
Germany) was applied for 1 h, followed by an HRP-
conjugated goat anti-rabbit antibody (1:100; DAKO, He-
verlee, Belgium) for 1 h. Sections were developed with
DAB liquid chromogen system (DAKO) and counterstained
with hematoxylin and Masson-Goldner’s trichrome staining,
according to the manufacturer’s protocol (Merck Chemi-
cals). Stained sections were imaged with a Nanozoomer
slide scanner 2.0 RS (Hamamatsu, SZK, Japan). These
sections were used to quantify the amount of perfused blood
vessels in and around the islets (within 200 mm) using Im-
ageJ software (http://rsb.info.nih.gov/ij/).
To assess the expression of insulin, glucagon, and the
endothelial marker CD31, immunohistochemistry was per-
formed on consecutive sections of islet-containing regions.
For this, heat-mediated antigen retrieval (pressure cooker,
80C, 30 min) was performed in sodium citrate buffer (pH
6.0). Sections were blocked with normal goat serum and
biotin/avidin blocking kit (Vector). Primary antibodies
against insulin (1:200, 1.5 h; Abcam), glucagon (1:100, o/n;
Vector), and CD31 (1:20, o/n; Abcam) were used. Second-
ary antibodies were Alexa 647 goat anti-guinea pig (1:500,
2 h; Invitrogen), biotin-SP-conjugated anti-rabbit (1:200,
1 h; Jackson ImmunoResearch, Suffolk, United Kingdom),




















































and Alexa-488-SA (Invitrogen). DAPI (Invitrogen) was
applied as nuclear counterstaining. Sections were imaged
with a Nikon A1 confocal microscope (Nikon BV).
Statistical Analyses
Results were presented as mean – standard error of the
mean. Statistical analyses were performed using SPSS ver-
sion 22 (SPSS, Chicago, IL). Kruskal–Wallis test was used
for multiple group comparisons ( p < 0.05, corrected for
multiple comparisons), and paired comparisons by means of
Mann–Whitney U-test were performed as post hoc test when
Kruskal–Wallis test indicated significant differences.
Results
Controlled formation of CIs
To fabricate the CIs, we used a nonadherent agarose
microwell culture platform, which has been developed in
our group for controlled cell aggregation.26 The microwells
were seeded with single islets before seeding with fluores-
cently labeled single cell suspensions of HUVECs, hMSCs,
or PC-hMSCs. One day after cell seeding, all single cells
present in the microwells were attached to the islet. Upon
culturing, the fluorescently labeled support cells became
more uniformly distributed over the islets (Fig. 1). More
detailed analysis of CI formation over time using 3D optical
sectioning on whole-mount islets revealed that 24 h after CI
formation, the cells attached to the islets as one or more cell
clusters (Fig. 2A–D). During prolonged cell culture, these
cell clusters migrated inward (Fig. 2E–H). Five days after
initial cell seeding, all conditions, regardless of the support
cell type, exhibited a core of hMSCs, HUVECs and hMSCs,
or PC-hMSCs, surrounded by a mantle of insulin and
glucagon-positive islet cells (Fig. 2E–H).
CIs maintain function in vitro
To assess whether the formation of CIs with different
proangiogenic cell populations affects islet functionality, the
insulin secretion response of the islets to a glucose challenge
was measured. For all conditions, we found that stimulation
with 16.7 mM glucose buffer increased the insulin secretion
two to threefold compared to basal insulin secretion at
1.7 mM glucose (Fig. 2I, J) at day 1 (Fig. 2I) and day 5
(Fig. 2J). One day after CI formation, a slight, although not
significant, improvement in the stimulation index was ob-
served compared to control islets. However, this trend was
not observed after 5 days of culture. At both time points, CIs
and control islets showed a proper return to basal insulin
secretion levels when exposed to a low, 1.7 mM, glucose
buffer. These results imply that CI formation does not alter
the islets’ insulin secretion capacity.
CIs show increased sprout formation in vitro
In vitro angiogenesis assays were performed to assess the
sprouting potential of CIs and control islets. For this, 8 h
FIG. 1. Islet composite formation with different types of support cells in nonadherent agarose microwell templates. Scale
bar: 400 mm. Color images available online at www.liebertpub.com/tea




















































after CI formation, CIs and control islets were flushed out of
the microwells and embedded in Matrigel (five different
islet donors) (Fig. 3) or fibrin gel (two different islet donors)
(Fig. 4). Sprouts emanating radially outward from the islets
could be observed in both sprouting matrices (Fig. 3A–D
and Fig. 4A–D). CM-DiI and CM-DiO labeling of the dif-
ferent cell types in case of HUVEC/hMSC-CIs revealed that
hMSCs and HUVECs are in close contact and that both cell
types contribute to sprout formation (Fig. 3E). Quantifica-
tion of sprout formation in Matrigel revealed significantly
more sprouts in the CI conditions compared to control islets
(Fig. 3F). In particular, the number of sprouts emanating
from PC-hMSC-CIs was significantly increased compared to
the other conditions. This difference remained prevalent
during the entire culture period, suggesting a persistent ad-
vantage of PC-hMSCs over the other observed cell types.
Substituting half of the hMSCs by HUVECs did not seem to
further improve sprout formation compared to hMSC-CIs. A
similar trend could be observed in fibrin gel (Fig. 4E), al-




The proangiogenic effect of CIs compared to control is-
lets was subsequently validated using an in vivo Matrigel
plug model. For this assay, CIs and control islets were flu-
shed out of the microwells 8 h after cell seeding, embedded
in 100mL growth factor-reduced Matrigel, and implanted
subcutaneously in the back of NMRI-nu mice. Two weeks
after implantation, grafts were retrieved and prepared for
histological analysis. Of the 36 implanted Matrigel plugs (9
per condition), 5 Matrigel plugs could not be recovered: 2 of
the control group, 2 of the HUVEC–hMSC-CI group, and 1
of the PC-hMSC-CI group.
Insulin trichrome staining showed directed invasion of
perfused vessels toward the islet grafts in case of CIs,
FIG. 2. Morphometric appearance and function of control islets and composite islets (CIs). (A–H) Representative 3D
reconstructions of optically sectioned control islets and CIs at day 1 (A–D) and day 5 (E–H) after CI formation, with DiI-
labeled support cells in red, beta-cells in white, and alpha-cells in green. The inserts represent an optical section through the
middle of the islet. (I–J) Stimulation index of high glucose (16.7 mM) and subsequently low glucose (1.7 mM) compared to
basal insulin secretion levels at 1.7 mM glucose for control islets and CIs at day 1 (I) and day 5 ( J) after CI formation.
Results are presented as mean – standard error of the mean (SEM) of three independent experiments. Scale bar: 100mm.
Color images available online at www.liebertpub.com/tea




















































whereas this was limited for the control islets (Fig. 5A–D).
Insulin/glucagon immunostaining of CI-containing plugs
showed scattered expression patterns of both hormones
throughout the islets (Fig. 5E–H), a cytoarchitecture typical
for human islets.28 In contrast to in vitro observations, CM-
DiI labeling of CI support cells did not reveal a core–mantle
structure of support cells and islet cells, respectively, when
implanted in vivo. Further immunostaining for CD31 was
performed to assess whether the CM-DiI-positive support
cells expressed this endothelial marker (Fig. 5I–L). Occa-
sionally, double-positive cells for CM-DiI and CD31 were
found (Fig. 5J–L inserts), although the majority of CM-DiI-
positive cells were CD31 negative.
Quantitative evaluation of vascularization in and around the
islets (within 200mm from the islet) (Fig. 6A) confirmed the
observation that vascularization was increased in case of CIs
compared to control islets (Fig. 6B). Only 7% of the islets in
the control group were vascularized (Fig. 6C), whereas this
was 32%, 19%, and 36% for HUVEC–hMSC-CIs, hMSC-CIs,
and PC-hMSC-CIs, respectively (Fig. 6C). In particular,
composite formation with either HUVECs combined with
hMSCs or PC-hMSCs resulted in a similar increase in vascu-
larization frequency of the islets (Fig. 6C). More detailed ex-
amination of vascular position in and around the vascularized
FIG. 3. Sprout formation in Matrigel. (A–D) Repre-
sentative phase-contrast microscopy images of control islets
(A) and CIs (B–D) taken 48 h after Matrigel embedding. (E)
Representative fluorescent image of human umbilical vein
endothelial cell/human mesenchymal stromal cell (HUVEC/
hMSC)-CI 48 h after Matrigel embedding with HUVECs la-
beled with DiO (green) and hMSCs with DiI (red). Both
HUVECs and hMSCs contribute to sprout formation (insert;
scale bar: 50mm). (F) Quantification of sprout formation 24,
48, and 96 h after Matrigel embedding. Results are presented
as mean – SEM of five independent experiments. ** <0.01
by Mann–Whitney U-test. Scale bar: 100mm. Color images
available online at www.liebertpub.com/tea
FIG. 4. Sprout formation in fibrin gel. (A–D) Repre-
sentative phase-contrast microscopy images of control islets
(A) and CIs (B–D) taken 48 h after fibrin gel embedding. (E)
Quantification of sprout formation 24, 48, and 96 h after
fibrin gel embedding. Results are presented as the mean of
two independent experiments. Scale bar: 100mm.




















































islets (Fig. 6D) revealed a general increase in the number of
vessels when HUVECs were added to the composite.
Discussion
In the current study, we present a facile and reproducible
method to fabricate CIs with proangiogenic cells as a
strategy to improve islet vascularization after subcutaneous
islet implantation. Most transplantation sites that can harbor
a sufficient amount of islets, such as the subcutaneous tissue,
are challenged by poor vascularization.29 To improve the
vascularization state of these sites, the possibility of creating
microvascular networks using mature endothelial cells de-
rived from vascular tissue has been suggested.30,31 How-
ever, the limited proliferative ability of these mature
endothelial cells hampers their clinical applicability. Pre-
vious studies have shown that cotransplantation of islets
with either MSCs or endothelial progenitor cells can also
induce neovascularization.10–18 These cells are easier to
harvest compared to mature endothelial cells and harbor
greater expansion potential,32 although a direct comparison
between different support cell types for islet revasculari-
zation at a clinically relevant transplantation site has not
been performed. Therefore, the study presented here di-
rectly compares the angiogenic potential of different cell
types for islet revascularization in an in vitro and in vivo
sprouting assay at a clinically relevant transplantation site
using growth factor-reduced Matrigel as a support trans-
plantation matrix.
Previously, we have shown that hMSCs can enhance
angiogenesis in Dex-g-HA gels after subcutaneous implan-
tation. The angiogenic potential of hMSCs could be further
increased by preconditioning them in EGM-2.24 Therefore,
in this study, we evaluate the effect of hMSCs and PC-
hMSCs on islet revascularization and compare their angio-
genic potential with mature endothelial cells (HUVECs)
supported by hMSCs, a combination shown to enhance the
vascularization in subcutaneously transplanted fibrin
plugs.33
Outlined in this study is a novel method of CI formation
using a nonadherent agarose microwell platform, which al-
lows for controlled seeding of support cells and islets in
individually separated microwells. In contrast to composite
formation in suspension culture, the method presented here
ensures that all initially seeded cells are incorporated into
the CI. In line with previous findings,9,34,35 we observe that
CI formation, regardless of the applied support cell type,
does not affect the glucose-stimulated insulin secretion ca-
pacity of the islets. The first day after CI formation, the
stimulation indices of CIs are slightly, although not signif-
icantly, higher compared to those of control islets. However,
this trend is not observed 5 days after coculture. This initial
FIG. 5. Microvasculature formation and islet composition after in vivo subcutaneous Matrigel plug assay. (A–D) Re-
presentative images stained for insulin and Masson-Goldner’s trichrome indicating perfused vessel formation in islet and CI
grafts. (E–L) Representative confocal microscopy images of islets and CIs with DiI-labeled support cells, stained for insulin
(white) and glucagon (green) (E–H) and for insulin (white) and CD31 (green) (I–L). Scale bar: 100 mm. Inserts represent
CD31-positive DiI-labeled support cells. Scale bar: 10 mm. Color images available online at www.liebertpub.com/tea




















































boost in the insulin secretion profile has been reported
previously by Dubiel et al., who cocultured porcine islets on
a monolayer of porcine liver microvascular endothelial
cells.36 They showed that the stimulated insulin secretion
improved for 2 days but not for more than 7 days. Similar to
Dubiel et al., we cultured the islets in islet culture medium,
which might not optimally support the function of the sup-
port cells. This might explain why we observe an initial
supportive effect, which is lost over time.
The cellular organization of CIs is dramatically changed
during in vitro culture when no supporting matrix, such as
Matrigel or fibrin gel, is used. We show that the support
cells preferentially aggregate before adhering to the islets,
an observation in line with previous reports.9,35 These ag-
gregates are engulfed over time by the islet cell mass, cor-
roborating earlier observations by Johansson et al., who
described similar internalization of endothelial cells upon
culturing.9 Such phenomena can be explained by the ‘‘dif-
ferential adhesion hypothesis’’; this postulates that a popu-
lation of motile mutually adhesive cells will spontaneously
reorganize to substitute weaker intercellular adhesions for
stronger ones until a configuration is found that maximizes
adhesive bonding.37 This results in a core of cells with strong
cohesive interactions surrounded by a shell of cells exhibiting
lower affinity. Our observation that the islet cells envelop the
support cells suggests that islet cells are less cohesive com-
pared to the support cells. This may be partly attributed to the
enzymatic procedure for islet isolation, which destroys the
islets’ basement membrane and alters the cellular integrin
expression.38 However, we observe an opposite pattern when
CIs are embedded in Matrigel or fibrin gel after 8 h of CI
formation, with extensive sprouting of the support cells ra-
dially outward to form an outer CI layer penetrating the
surrounding gel. In addition, after in vivo implantation of CIs
in supporting Matrigel plugs, intact islet cell clusters are
observed surrounded by outwardly migrating support cells.
FIG. 6. Vascular morphometry of control islets and CIs. (A) Image segmentation to determine the number of blood
vessels in the insulin-positive islet area (red) and within a radius of 200 mm (divided into 50-mm sections as represented in
blue). (B) Number of blood vessels per islet for uncoated control islets and CIs. (C) Frequency plot for vascularization of
control islets and CIs. (D) Mean number of vessels within vascularized islets. Results are presented as mean – SEM. **<0.01
by Mann–Whitney U-test. Scale bar: 100mm. Color images available online at www.liebertpub.com/tea




















































These observations suggest that sufficient cell–matrix inter-
actions can counteract the cell–cell-based differential adhe-
sion phenomenon observed when no matrix is used.
Established in vitro models of angiogenesis involve the
monitoring of capillary-like structure formation in three-
dimensional gels mimicking the extracellular matrix, such
as Matrigel,39 fibrin gel,9,40,41 or collagen gel.42 Using two
of these model systems, Matrigel and fibrin gel, we dem-
onstrate the induction of sprout formation of CIs over time.
The observation that control islets sprout in fibrin gel is in
line with previous reports.9,36,41,43 To our knowledge, no
studies have monitored sprouting of control islets in Ma-
trigel. The improved performance in the sprouting capacity
of uncoated islets in fibrin compared to Matrigel could be
explained by either the difference in matrix composition or
stiffness, shown to influence sprout formation of mature
endothelial cells both in vitro42,44–47 and in vivo,33 or the
expression of a specific set of fibrinolytic enzymes in in-
traislet endothelial cells, specifically enabling successful
remodeling of the fibrin matrix.47–49 Our results further
indicate that hMSCs, either naive or preconditioned, sig-
nificantly enhance sprout formation in vitro compared to
HUVEC–hMSC-CIs or control islets. Cellular invasion and
migration in Matrigel, which primarily consists of laminin,
collagen IV, and enactin, are mainly regulated by matrix
metalloprotease (MMP) activity.50 It has been shown that
bone marrow-derived hMSCs express higher levels of MMPs,
such as MT1-MMP and MMP-2, compared to HUVECs.40
The twofold reduction of hMSCs in the HUVEC–hMSC-CI
group compared to the hMSC- and PC-hMSC-CI group
likely results in a lower expression of proteolytic enzymes,
accounting for the observed reduction in in vitro sprout
formation.
Analysis of in vivo implanted Matrigel plugs reveals the
highest number of perfused lumen-containing structures in
and around the islets when islets are coimplanted with a
mixture of HUVECs and hMSCs. Although contrary to our
in vitro findings, this observation is in line with a previous
report, where subcutaneously transplanted fibrin plugs
containing a mixture of hMSCs and HUVECs exhibited an
increased number of perfused vessels compared to con-
structs containing either hMSCs or HUVECs alone.47 The
exact mechanisms by which the hMSC–HUVEC combi-
nation results in improved neogenesis remain unclear.
However, hMSCs and HUVECs secrete numerous soluble
factors, such as vascular endothelial growth factor and
bFGF,51 and extracellular matrix (ECM)-remodeling en-
zymes, such as MMPs.52 All these factors contribute to
endothelial cell survival, tip cell migration, proliferation,
endothelial tubulogenesis, and/or vascular maturation,52–54
and many of them have been shown to have increased ex-
pression in HUVEC/HMSC cocultures.40 Others suggest
that hMSCs are able to differentiate into a pericyte or
smooth muscle-like cell and stabilize newly formed ves-
sels,55 but further studies are warranted.
Although an increasing trend is observed in the per-
centage of vascularized islets when hMSCs or PC-hMSCs
are used compared to control islets, we do not observe a
significant difference in perfused vessel density. This is in
contrast to previous studies reporting a significant im-
provement in revascularization rate when islets are co-
transplanted with bone marrow-derived MSCs underneath
the renal capsule11,13 or intrahepatically.12 The reason for
this discrepancy is likely multifactorial. First of all, since
the subcutaneous site is poorly vascularized compared to
the renal subcapsular and intrahepatic transplantation sites,
the proangiogenic effect of hMSCs might be unable to
induce islet revascularization at this transplantation site
within the observed period. Furthermore, growth factor-
reduced Matrigel as a supporting matrix imposes an addi-
tional barrier for both the diffusion of soluble proangio-
genic factors and the infiltration of blood vessels. Another
factor that could have influenced the revascularization
process is the distribution of the support cells within the
hydrogel. In the current study, the support cells are con-
fined around the islets. However, we have previously
shown that when hMSCs and PC-hMSCs are homoge-
neously distributed throughout Dex-g-HA gels, these cells
can significantly improve the vascularization in these
gels.24 Although Dex-g-HA was used in lieu of Matrigel,
possibly accounting for the difference in outcome, we
hypothesize that the uniform cellular distribution created a
more suitable environment for recruitment and infiltration
of blood vessels because of a more homogeneous presen-
tation of angiogenic and proteolytic factors.
Comparing the in vitro and in vivo results, we observe a
discrepancy in angiogenesis. In vivo, the highest number of
perfused lumen in and around the islets is observed when
islets are coimplanted with a mixture of HUVECs and
hMSCs, whereas in vitro sprout formation is highest for the
PC-hMSC-CIs. As mentioned before, in vitro tube formation
is largely influenced by the invasive capacity of the cells by
proteolytic enzyme-mediated ECM degradation. Although
ECM degradation is an important component for in vivo
angiogenesis, the process of de novo blood vessel formation
involves a complex interplay between multiple cell types
from host and donor, growth factors, enzymes, and extra-
cellular matrix molecules, a level of complexity not mim-
icked during in vitro assays and therefore precludes an
accurate prediction of in vivo outcome. Our findings high-
light the importance and necessity of verifying in vitro
studies with in vivo models to reliably predict, in this case,
revascularization outcomes.
In conclusion, this study presents a controlled method to
fabricate CIs to study the angiogenic potential of different
support cells. Using a subcutaneous Matrigel plug assay, we
demonstrate that CIs with hMSCs and HUVECs exhibit a
higher angiogenic potential compared to control islets or
islets combined with hMSCs or PC-hMSCs. However, for
this method to be clinically applicable, further efforts are
required to identify a clinically relevant proangiogenic cell
source. Regardless, we show here the therapeutic potential
of CIs with proangiogenic support cells to enhance islet
revascularization at a clinically relevant, although poorly
vascularized, transplantation site.
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